Skip to main content
OpenTrials
Completed

NCT Number: NCT03840603

Impact on PCT+ FilmArray RP2 Plus Use in LRTI Suspicion in Emergency Department

The real-time reporting of PCT results along with viral PCR data from the FilmArray® Respiratory Panel 2 plus in conjunction with an antimicrobial stewardship plan will aid in the proper withholding or withdrawing of antibiotics (ATB) when the collective data is indicative of a viral Lower Respiratory Tract Infection (LRTI).

The addition of the FilmArray® RP2plus diagnostic test indicating the presence of a viral infection in subjects presenting with respiratory symptoms could improve the confidence to care-providing physicians to withhold prescribing antibiotics.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

AP-HP Pitié la salpétrière

Paris, France

About this study

In the emergency room a nasopharyngeal swab sample will be collected from subjects with a suspected LRTI for the FilmArray respiratory panel assay plus a blood sample for the PCT assay if the PCT measurement has not been already prescribed.

The FilmArray® Respiratory Panel 2 plus (RP2plus) is a multiplexed nucleic acid test intended for use with FilmArray® 2.0 or FilmArray® Torch systems for the simultaneous qualitative detection and identification of multiple respiratory viral and bacterial nucleic acids in nasopharyngeal swabs (NPS) obtained from individuals suspected of respiratory tract infections.

Both results will be reported in real-time to the treating physicians with the recommendation to withhold or withdraw antibiotics if:

  • PCT<0.10 µg/L with either a positive (with a viral respiratory pathogen) or negative FilmArray assay or
  • PCT<0.25 µg/L and FilmArray positive with a viral respiratory pathogen. For the control arm, patients will benefit from the usual care of patients with suspected LRTI at the discretion of the attending physician. Care may entail a CRP and/or a PCT measurement, but no nasopharyngeal swab sampling.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • 1. Subject is ≥ 18 years of age attending the ED with LRTI symptom defined as at least one among:
  • sweats, chills, body aches and pain, temperature >38°C) and at least one among:
  • cough, sputum production, dyspnea, chest pain, altered breath sounds at auscultation.
  • 2. Subject signs informed consent

Exclusion criteria

  • Subject is a prisoner
  • Subject is a Pregnant
  • Subject has no social insurance
  • Subject is enrolled in end of life care
  • Subject refuses to participate in study procedures
  • Subject is already enrolled (each patient will only be tested one time with the FilmArray® RP2plus)
  • Subject has a contraindication (per the discretion of the attending physician) to a nasopharyngeal swab (for example, nose bone fracture or recent history of maxilla-facial surgery)

Treatment and study plan

Film Array RP2 Assay guided

Diagnostic Test

Nasopharyngeal swab sample collected from subjects with a suspected LRTI for the Film Array RP2 assay plus a blood sample for the PCT assay.

Primary outcomes

  1. Duration of total antibiotic exposure

    Time frame: First 28 days

    The primary endpoint in this study is the duration of total antibiotic exposure (measured in days) in the first 28 days after randomization.

Secondary outcomes

  1. Initiation of an antibiotic therapy

    Time frame: First 28 days

    initiation of an antibiotic therapy in the first 28 days after the reporting test results to clinicians (both ATB given in the ED or given a prescription for an ATB to get at the pharmacy)

  2. Protocol "failure" within 15 days of randomization

    Time frame: within 15 days

    protocol "failure" within 15 days of randomization (defined as worsening of LRTI and/or receipt of antibiotics in cases where no initial ATB treatment was administered, and/or unplanned ED's re-admission for the same complaint)

Sponsors and collaborators

Lead sponsor

BioMérieux

Industry

Collaborators

  • APHP
  • BioFortis

Registry information

Official study title

PROARRAY : Impact on PCT+ FilmArray RP2 Plus Use in LRTI Suspicion in Emergency Department

Acronym: PROARRAY

Important dates

Study start
2019
Primary completion
2019
Study completion
2022
First posted
Feb 15, 2019
Registry last updated
Jan 31, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.